South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

triomed (pty) ltd - capsule - each capsule contains cefaclor (monohydrate) equivalent to 250,0 mg cefaclor

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

triomed (pty) ltd - capsule - each capsule contains cefaclor (monohydrate) equivalent to 500,0 mg cefaclor

European Union - English - EMA (European Medicines Agency)

takeda pharmaceuticals international ag ireland - prucalopride succinate - constipation - other drugs for constipation - resolor is indicated for symptomatic treatment of chronic constipation in adults in whom laxatives fail to provide adequate relief.

Kenya - English - Pharmacy and Poisons Board

sance laboratories vi/51b, p.b. no.2, kozhunaval, pala, kottayam- - cefixime - capsule - 400mg - beta-lactamantibacterials: third-generation

Kenya - English - Pharmacy and Poisons Board

sance laboratories vi/51b, p.b. no2 kozhuvanal, pala kottayam-686523 - cefixime-usp - capsule - 400mg - beta-lactamantibacterials: third-generation

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - cefaclor monohydrate, quantity: 393.4 mg (equivalent: cefaclor, qty 375 mg) - tablet, modified release - excipient ingredients: mannitol; hypromellose; hyprolose; methacrylic acid copolymer; stearic acid; magnesium stearate; propylene glycol; purified talc; colour - indications as 16 december 1997: keflor cd is indicated for the treatment of the following types of infections caused by susceptible organisms, in adults and children aged 12 years or older: acute bronchitis and acute exacerbations of chronic bronchitis; upper respiratory infections, including pharyngitis, tonsillitis and acute bacterial sinusitis: community-acquired pneumonia of mild to moderate severity (excluding atypical pneumonia); symptomatic lower urinary tract infections, including cystisis; skin and skin structure infections. note 1. penicillin in the usual drug of choice in the treatment and prevention of streptoccocal infections, including the prophylaxis of rheumatic fever. keflor cd is generally effective in the eradication of streptococci from the oropharynx; however, substantial data establishing the efficacy of keflor cd in the subsequent prevention of rheumatic fever are not available. 2. bacteriological studies to determine the causative organism and its susceptibility to cefaclor should be

Israel - English - Ministry of Health

biotis ltd - prucalopride as succinate - film coated tablets - prucalopride as succinate 1 mg - prucalopride - prucalopride - resolor is indicated for symptomatic treatment of chronic constipation in adults in whom laxatives fail to provide adequate relief

Israel - English - Ministry of Health

biotis ltd - prucalopride as succinate - film coated tablets - prucalopride as succinate 2 mg - prucalopride - prucalopride - resolor is indicated for symptomatic treatment of chronic constipation in adults in whom laxatives fail to provide adequate relief

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - cefaclor monohydrate, quantity: 52.45 mg/ml (equivalent: cefaclor, qty 50 mg/ml) - oral liquid, powder for - excipient ingredients: methylcellulose; sodium lauryl sulfate; dimeticone 350; xanthan gum; erythrosine; sucrose; pregelatinised starch; flavour - keflor is indicated for the treatment of the following types of infections caused by or likely to be caused susceptible organisms: lower respiratory infections, including pneumonia, bronchitis and exacerbations of chronic bronchitis. upper respiratory infections, including pharyngitis, tonsillitis and otitis media. skin and skin structure infections. urinary tract infections, including pyelonephritis and cystitis. note: 1. penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. keflor appears to be effective as phenoxymethul penicillin in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cefaclor in the subsequent prevention of rheumatic fever are not available at present. 2. appropriate culture and susceptibility studies should be performed to determine susceptibility of the causative organisms to cefaclor.